Login / Signup

A prospective, open-label, interventional study protocol to evaluate treatment efficacy of nivolumab based on serum-soluble PD-L1 concentration for patients with metastatic and unresectable renal cell carcinoma.

Yukari BandoNobuyuki HinataTakashi OmoriMasato Fujisawa
Published in: BMJ open (2019)
UMIN000027873.
Keyphrases
  • open label
  • study protocol
  • renal cell carcinoma
  • clinical trial
  • randomized controlled trial
  • phase ii
  • locally advanced
  • radiation therapy
  • rectal cancer
  • double blind